Age group | Pneumococcal CAP (%) | Annual incidence (per 100 000) | VT serotypes (%) | NVT serotypes (%) | OR of VT versus NVT CAP (95% CI) | p Value |
16–44 (n=136) | 64 (47.1) | 12.1 | 7 (10.9) | 38 (59.4) | Reference | – |
45–64 (n=192) | 76 (39.6) | 27.0 | 14 (18.4) | 41 (53.9) | 1.9 (0.7 to 5.1) | 0.231 |
65–74 (n=209) | 72 (34.4) | 70.6 | 17 (23.6) | 29 (40.3) | 3.2 (1.2 to 8.7) | 0.024 |
75–84 (n=242) | 92 (38.0) | 134.5 | 18 (19.6) | 39 (42.4) | 2.5 (0.9 to 6.7) | 0.066 |
85+ (n=141) | 62 (44.0) | 274.1 | 16 (25.8) | 23 (37.1) | 3.8 (1.4 to 10.6) | 0.011 |
All ages (n=920) | 366 (39.8) | 36.5 | 72 (19.7) | 170 (46.4) | – | – |
CAP, community-acquired pneumonia; NVT, non vaccine-type (serotypes not included within the 7-valent childhood pneumococcal vaccine); VT, vaccine-type (serotypes included within the 7-valent childhood pneumococcal vaccine (4, 6B, 9V, 14, 18C, 19F, 23F)).